Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis.

Day, Robert; Dong, Weijia; Panetta, Rosemarie; Kraicer, Jacob; Greenwood, Michael T.; Patel, Yogesh C.

doi:10.1210/endo.136.11.7588263

Cited by 77 publications

(44 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rat pituitary cells, as well as the GH3 pituitary cell line, express all five sst mRNA (31,34). In situ hybridization combined with immunohistochemistry (35) and reverse transcription (RT)-PCR in purified somatotrophs (36) revealed that rat somatotrophs express mRNA for all five ssts. In situ hybridization analysis revealed a relatively high level of sst4 (35) and sst5 (35,36) mRNA expression in somatotrophs as well as an important although lower expression of sst2.…”

Section: Introductionmentioning

confidence: 99%

“…In situ hybridization combined with immunohistochemistry (35) and reverse transcription (RT)-PCR in purified somatotrophs (36) revealed that rat somatotrophs express mRNA for all five ssts. In situ hybridization analysis revealed a relatively high level of sst4 (35) and sst5 (35,36) mRNA expression in somatotrophs as well as an important although lower expression of sst2. A heterogeneous expression of SRIH receptor subtypes has also been demonstrated in human pituitary tumours (37)(38)(39).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Species differences between male rat and ram pituitary somatostatin receptors involved in the inhibition of growth hormone secretion

Briard

Dutour

Epelbaum

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

The sheep is a valuable model in which to study GH neuroregulation as its pattern of GH secretion is very close to that in humans. Furthermore, important differences in somatostatin (SRIH) action between rats and sheep have been found previously. Our goal was to compare in male rat and ram pituitaries the binding characteristics of somatostatin receptors and the effect of SRIH and 17 analogues on GH release. Using radioautography, SRIH binding was seen to be evenly distributed over the anterior pituitary of both species. In the binding assay, binding sites were three times more concentrated in rats than in sheep. Important interspecies differences in the action of SRIH and its analogues were found: they inhibited GH at lower concentrations in rats than in sheep. Seven peptides displayed greater inhibitory ability in sheep than in rats while three were more potent in rats. Agonistic potencies to inhibit GH release in rats were correlated with somatostatin receptors subtype 2 (sst2) affinities. Our data confirm and extend the quantitative differences between rat and sheep in SRIH inhibitory action on GH secretion and confirm that ligand-binding properties of a given receptor subtype cannot be extrapolated across species. European Journal of Endocrinology 137 545-555

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Species differences between male rat and ram pituitary somatostatin receptors involved in the inhibition of growth hormone secretion

Briard

Dutour

Epelbaum

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In another study, sst5 mRNA was found in 38% of normal corticotrophs, and sstr2 in only 3% [26], whereas Mezey and coworkers [27] demonstrated sst2 in a large population and sstr5 in a small population of corticotrophs. Somatostatin influences ACTH secretion in pituitary cells in culture through inhibition of CRF-stimulated adenyl cyclase activity, and by preventing stimuluselicited calcium influx [28] over sstr2 and sstr5 receptor subtypes but not over sstr1, sstr3 or sstr4 [29].…”

Section: Discussionmentioning

confidence: 91%

Pituitary ACTH cells in female rats after neonatal treatment with SRIH-14.

Milošević

Nestorović²,

Terzić³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The prolonged effects of neonatal SRIH-14 treatment on pituitary ACTH cells were investigated. Neonatal female rats were injected subcutaneously with SRIH (20 μg/100g b.w.) every 12 hours for five consecutive days (3 rd -7 th day of life). Groups of rats were then killed at the juvenile (16 th day), peripubertal (38 th day) or adult (80 th day) stage. ACTH cells were visualized using the peroxidase-antiperoxidase immunocytochemical procedure. Morphometry and stereology were used to evaluate the ACTH-immunoreactive cell volume and volume density. The histological and immunocytochemical characteristics of ACTH cells in neonatally treated females were changed in all examined periods. Thus, SRIH-14 induced significant (p<0.05) decreases of ACTH cell volume in juvenile, peripubertal and adult rats by 26%, 39% and 14%, respectively, in comparison to the corresponding controls. The volume density of ACTH cells was also diminished (by 31%; p<0.05) at the juvenile stage in comparison with the corresponding controls. In peripubertal and adult rats, the volume densities of ACTH cells were somewhat lower (17% and 14%, respectively), but the decreases did not reach statistical significance. These findings suggest that neonatal treatment with SRIH-14 exerts a marked prolonged inhibitory effect on ACTH cell morphology extending to the adult period of life.

show abstract

“…Yet in another study only 38% of corticotrophs expressed somatostatin receptor subtype 5 (sst5) and 3% expresses somatostatin receptor subtype 2 (sst2) (67). While in contrast Smith et al found a predominance of sst2 rather than sst5 (68).…”

Section: Somatostatin Analoguesmentioning

confidence: 87%

Pharmacological management of Cushing's syndrome: an update

Dang

Trainer

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

The treatment of choice for Cushing's syndrome remains surgical. The role for medical therapy is twofold. Firstly it is used to control hypercortisolaemia prior to surgery to optimize patient's preoperative state and secondly, it is used where surgery has failed and radiotherapy has not taken effect. The main drugs used inhibit steroidogenesis and include metyrapone, ketoconazole, and mitotane. RESUMOManejo Farmacológico da Síndrome de Cushing: Uma Atualização. O tratamento de escolha para a síndrome de Cushing ainda é a cirurgia. O papel da terapia medicamentosa é duplo: ele é usado para controlar o hipercortisolismo antes da cirurgia e otimizar o estado pré-operatório do paciente e, adicionalmente, quando ocorre falha cirúrgica e a radioterapia ainda não se mostrou efetiva. Os principais medicamentos são empregados para inibir a esteroidogênese e incluem: metirapona, cetoconazol e mitotano. Medicamentos visando o eixo hipotálamo-hipofisário têm sido investigados, mas seu papel na prática clínica permanece limitado, embora o agonista PPAR-γ e análogo de somatostatina, som-230 (pasireotídeo), requeira estudos adicionais. A única droga que age perifericamente no receptor glicocorticóide é a mifepristona (RU486). O manejo da síndrome de Cushing deve envolver uma combinação terapêutica atuando em diferentes vias da hipercortisolemia, mas o monitoramento dessa terapia ainda permanece um desafio. (Arq Bras Endocrinol Metab

show abstract

Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis.

Cited by 77 publications

References 12 publications

Species differences between male rat and ram pituitary somatostatin receptors involved in the inhibition of growth hormone secretion

Species differences between male rat and ram pituitary somatostatin receptors involved in the inhibition of growth hormone secretion

Pituitary ACTH cells in female rats after neonatal treatment with SRIH-14.

Pharmacological management of Cushing's syndrome: an update

Contact Info

Product

Resources

About